beta-endorphin and Affective-Disorders--Psychotic

Topics: Affective Disorders, Psychotic; Animals; beta-Endorphin; Bipolar Disorder; Clinical Trials as Topic; Double-Blind Method; Endorphins; Growth Hormone; Humans; Hydrocortisone; Methylphenidate; Models, Psychological; Naloxone; Prolactin; Schizophrenia

Topics: Affective Disorders, Psychotic; Animals; Anxiety; beta-Endorphin; Catatonia; Dyskinesia, Drug-Induced; Electroconvulsive Therapy; Endorphins; Humans; Mental Disorders; Narcotic Antagonists; Opioid-Related Disorders; Pain; Rats; Receptors, Opioid; Renal Dialysis; Schizophrenia; Stress, Psychological

It has been demonstrated by a double blind placebo-controlled study that transcranial electric treatment (TET) by means of combination of direct current and pulse current and pulse current at a frequency of 70-80 Hz is an effective method of correcting affective disorders (anxiety, depressions) in patients suffering from alcoholism. The therapeutic effects of TET are coupled with changes in GABA and monoamine metabolism rather than in beta-endorphin as well as with a decrease of the latent period of the occurrence of alpha-rhythm after eyes closing.

Topics: Adult; Affective Disorders, Psychotic; Alcoholism; beta-Endorphin; Brain; Double-Blind Method; Electric Stimulation Therapy; gamma-Aminobutyric Acid; Humans; Middle Aged; Monoamine Oxidase; Psychoses, Alcoholic

Topics: Affective Disorders, Psychotic; Animals; beta-Endorphin; Bipolar Disorder; Clinical Trials as Topic; Double-Blind Method; Endorphins; Growth Hormone; Humans; Hydrocortisone; Methylphenidate; Models, Psychological; Naloxone; Prolactin; Schizophrenia

The subjects were 13 psychiatric inpatients with tardive dyskinesia. Each subject participated in two sessions. Either naloxone (10 mg) or placebo was administered intravenously during each session. In a subset of subjects (n = 7), blood samples for beta-endorphin were drawn before and at 30 and 60 minutes after the injection. The Abnormal Involuntary Movement Scale was administered before and at 10, 20, 40, 60, 120, and 360 minutes after the injection. Double-blind procedures were maintained throughout the experiment. Neither naloxone nor placebo had any appreciable effect on the involuntary movements. Naloxone elicited a significant increase in the plasma beta-endorphin.

Topics: Adult; Affective Disorders, Psychotic; Aged; beta-Endorphin; Dyskinesia, Drug-Induced; Endorphins; Female; Humans; Male; Middle Aged; Naloxone; Psychotic Disorders; Receptors, Dopamine; Schizophrenia

Topics: Adrenocorticotropic Hormone; Adult; Affective Disorders, Psychotic; beta-Endorphin; beta-Lipotropin; Endorphins; Female; Humans; Male; Middle Aged; Pituitary Gland; Pro-Opiomelanocortin; Schizophrenia

Clinical and biochemical data suggest a link between anorexia nervosa (AN) and primary affective disorders (PAD). In 14 female patients, aged 15-40 years, with 7-month to 11-year histories of AN, we studied circadian cortisol periodicity, response to the dexamethasone suppression test (DST), and plasma levels of beta-endorphin and beta-lipotropin before and after desimipramine therapy. Possible correlations were sought among neuroendocrine impairments, weight loss, and depressive symptomatology. Impaired circadian cortisol periodicity, blunted DST response, and increased beta-endorphin plasma levels, observed in a subgroup of patients, could not be related to weight loss, either before or after therapy. Instead, a trend toward a relationship between neuroendocrine impairments and depressive symptoms was observed before and after treatment.

Topics: Adolescent; Adult; Affective Disorders, Psychotic; Anorexia Nervosa; beta-Endorphin; beta-Lipotropin; Desipramine; Dexamethasone; Endorphins; Female; Humans; Hydrocortisone; Hypothalamo-Hypophyseal System

Mean plasma levels of beta-endorphin (beta EP), beta-lipotropin (beta LPH) and ACTH were significantly higher in 22 patients with primary affective disorders (PAD) and in 2 schizoaffective subjects off therapy since 10 days than in 22 age- and sex-matched healthy controls. Desimipramine therapy (50-100 mg/day per os for 3-5 weeks) induced in parallel psychological improvement and fall in beta LPH-beta EP in 6 of 8 PAD patients treated, and a normalization of beta EP-beta LPH levels with minimal mood improvement in the 2 schizoaffective subjects. These results indicate that the opioid levels are increased in PAD and schizoaffective patients and normalized by the desimipramine therapy in those patients in whom the affective disorders improved.

Topics: Adrenocorticotropic Hormone; Adult; Affective Disorders, Psychotic; Aged; beta-Endorphin; beta-Lipotropin; Bipolar Disorder; Desipramine; Endorphins; Female; Humans; Male; Middle Aged; Psychotic Disorders

beta-Endorphin immunoreactivity was measured in cerebrospinal fluid of 75 medication-free subjects: normal, depressed, schizophrenic, and anorexic. No significant differences in beta-endorphin immunoreactivity were found. Affinity extraction chromatography revealed beta-lipotropin and beta-endorphin, but no apparent precursors.

Topics: Adolescent; Adult; Affective Disorders, Psychotic; Aged; Anorexia Nervosa; beta-Endorphin; Bipolar Disorder; Depressive Disorder; Endorphins; Female; Humans; Male; Middle Aged; Reference Values; Schizophrenia

Beta-Endorphin (0.3 or 0.6 nanomoles) was infused into the A10-ventral tegmental area (VTA) of male Wistar rats previously treated for 6 days with either morphine sulfate or lactose via subcutaneously implanted silastic pellets. Beta-Endorphin microinfusions occurred at 24 and 96 hours after pellets were removed. Profound changes in locomotor response to beta-endorphin were found, with morphine-pretreated rats showing a spontaneous switch from hyporesponsiveness to hyperresponsiveness over 72 hours, compared to lactose-pretreated controls. These findings may reflect on current biochemical theories regarding the "switch" process in bipolar affective disease. The data can be viewed within a heuristic model of receptor changes which may underlie the transition from depression to mania.

Topics: Affective Disorders, Psychotic; Animals; beta-Endorphin; Bipolar Disorder; Dextroamphetamine; Disease Models, Animal; Endorphins; Humans; Limbic System; Male; Morphine; Motor Activity; Naloxone; Neural Pathways; Rats; Rats, Inbred Strains; Receptors, Dopamine; Substance Withdrawal Syndrome; Tegmentum Mesencephali

Topics: Adult; Affective Disorders, Psychotic; Aged; beta-Endorphin; Depressive Disorder; Dexamethasone; Electroconvulsive Therapy; Endorphins; Female; Humans; Hydrocortisone; Lipoproteins, LDL; Male; Middle Aged; Radioimmunoassay